CRISPR Therapeutics’ FDA Approval for CASGEVY™
CRISPR Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving CASGEVY™ (exagamglogene autotemcel [exa-cel]), a groundbreaking CRISPR/Cas9 gene-edited cell therapy. This approval makes CASGEVY available for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older. Approximately 1,000 patients in the U.S. are now eligible for […]
RoslinCT and the Revolutionary CRISPR-Based Gene Therapy CASGEVY™
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has achieved a groundbreaking milestone in the field of medical science. Building on its legacy since the cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has now been entrusted with the manufacturing of the first-ever U.S. Food and […]